Introduction
In vivo T-cell depletion with antithymocyte globulin (ATG) as part of the conditioning regimen in patients undergoing hematopoietic stem cell transplantation (HSCT) from unrelated donors can be used as a strategy to lower the incidence of acute and chronic graft-versus-host disease (GVHD). [1] [2] [3] Recently, our group demonstrated that ATG Fresenius (ATG-F) leads to a significant reduction of GVHD without increase of relapse or graft failure in good risk patients with myeloid leukemia after stem cell transplantation from matched related donors. 4 Different preparations of antithymocyte antibodies (horse vs rabbit origin) currently used may have different effects on the incidence of GVHD and relapse after HSCT. This might be related to their different potential for affecting cytokine release during conditioning. 5 Apart from the well-known side effects of ATG such as chills and fever, 6 ,7 the effects of ATG on the coagulation cascade are not well defined. Some authors have reported the development of a coagulopathy after injection of different ATG or anti-T lymphocyte antibodies (ALG) preparations involving platelet aggregation and thrombocytopenia, 8, 9 depletion of fibrinogen and factor VII, 10 increased D-Dimer levels with fibrinolytic impairment, 11 prolonged coagulation tests 12 and disseminated intravascular coagulation (DIC). 13, 14 However, others have not been able to demonstrate an association between ATG therapy and DIC. 15 Most of these studies were performed either in animal models 9 or in patients who received ALG as prophylaxis or treatment of acute renal allograft rejection after renal transplantation. 11, 12, 16 So far only one study reporting on the short-term toxicity of ATG-F in patients undergoing HSCT has been published. 13 Hemostatic alterations during the early or later course of HSCT with signs of hypercoagulability and endothelial dysfunction [17] [18] [19] are frequently observed and associated with an increased incidence of severe complications such as vascular-occlusive-disease of the liver (VOD), [20] [21] [22] diffuse alveolar haemorrhage, 23 thrombotic-thrombocytopenic purpura (TTP) 24 and GVHD. 19 Therefore, the aim of our study was to focus and assess the effect of ATG-F on the hemostatic system as a part of different preparative conditioning regimens in patients undergoing HSCT from HLA-matched unrelated donors for various hematological malignancies.
Material and methods

Patients
The study group (ATG group) consisted of 12 patients with various hematological malignancies undergoing HLAmatched allogeneic HSCT from unrelated donors between April 2001 and April 2002 at the University Hospital Hamburg-Eppendorf. The control group consisted of 10 patients (non-ATG group) who underwent allogeneic HSCT from their HLA-identical siblings. Patients in the control group did not receive in vivo T-cell depletion with ATG-F as part of their preparative regimen. The two groups showed a virtually identical distribution in terms of gender, median age, stem cell source and underlying disease. Therefore, identical conditioning regimens (7ATG) were used. Patient characteristics are presented in Table 1 . None of the patients with acute myeloid leukemia had a diagnosis of acute myeloid leukemia (AML) M3 according to the FAB classification.
Conditioning regimens
Patients with acute lymphoblastic leukemia (ALL, n ¼ 5) received total body irradiation (TBI, 12 Gy) plus etoposide 
GVHD prophylaxis
GVHD prophylaxis in both groups consisted of cyclosporin A (3 mg/kg, day À1 to 6 months after transplantation) and methotrexate (10 mg/m 2 ) on days 1, 3 and 6 after transplantation. The dose of cyclosporin A was adjusted to cyclosporin A serum levels. ATG of rabbit source (ATG-F, Fresenius, Graefeling, Germany) was given to all the 12 patients in the ATG group as a continuous 12-h infusion once a day on days À3, À2 and À1 in the following dosages: 10 mg/kg (n ¼ 3), 15 mg/kg (n ¼ 3), 20 mg/kg (n ¼ 1), 30 mg/kg (n ¼ 4). One patient received 10 mg/kg on days À4 to À1. For the prevention of ATG-associated anaphylactic reactions, intravenous methylprednisolone (2 mg/kg) and clemastine (4 mg) were administered to all patients before the ATG infusion was started.
Supportive care
All patients were nursed in single rooms with hepa-filtered air. Antibiotic prophylaxis consisted of ofloxacin or ciprofloxacin and antifungal prophylaxis was provided with fluconazole and in case of prior mycotic infection with amphotericin B or caspofungin. Additionally, acyclovir and trimethoprim/sulfamethoxazole were used as prophylaxis against herpes and Pneumocystitis carinii infection.
All patients received hematopoietic growth factor (G-CSF, 5 mg/kg) intravenously starting on day 1 after transplantation until the absolute granulocyte count was 41.0/nl for three consecutive days.
Laboratory assays
For analysis, blood samples anticoagulated with 3.2% sodium chloride citrate (Sarstedt, Nu¨mbrecht, Germany) were collected between 8.00 and 9.00 am local time from triple-lumen central venous lines, which were flushed before blood sampling with at least 10 ml sodium chloride 0.9%. Alternatively, blood samples were collected by venipuncture with a 21 G needle (Sarstedt, Nu¨mbrecht, Germany). Blood samples used for plasminogen activator inhibitor antigen type 1 (PAI-1) analysis were collected in vacutainer containing sodium citrate with a special calibrated buffer system (Stabilyt s , Wak Medical, Steinbach, Germany) and put on ice until centrifugation. Blood samples were obtained before the start of each conditioning regimen (day À9), immediately before and during ATG-F therapy on days À3, À2, À1 and 0 and on day 3 after HSCT. Blood samples were centrifugated at 4000 g for 10 min at 41C and stored in aliquots at À801C until used. PAI-1 was determined using a commercially available solid-phase immunoassay (Technoclone, Vienna, Austria, normal range: 30-80 ng/ml). Soluble thrombomodulin (sTM) was measured with a commercially available sandwich enzyme immunoassay based on monoclonal antibodies (Asnieressur-Seine, France, normal range: 24-45 ng/ml). Tissue factor (TF) was determined using a commercially available ELISA kit based on a monoclonal murine anti-human 
Statistical analysis
For statistical analysis (WIN-STAT-software, Kalamia, Cambridge, MA, USA), a Student's-T-test for unpaired data was applied. A P-value of o0.05 was considered to be statistically significant.
Results
Compared to the non-ATG group, we observed a significant rise in D-Dimer levels ( Table 2) on days À2 and À1 in patients treated with ATG-F. ATG therapy was initiated in all but one patient on day À3. At 24 and 48 h after ATG treatment had been initiated, increased D-Dimer levels were found in all patients treated with ATG-F. This effect was independent from the different conditioning regimens and ATG dosages (data not shown). As shown in Figure 1 , D-Dimer elevation started on day À2 and ceased off rapidly after cessation of ATG-F on day 0. On day À3 no significant difference in D-Dimer levels could be observed between the two groups because blood samples were taken before the first ATG administration. Simultaneously with the maximum increase of D-Dimer levels on day À2, we observed a significant rise in TF, sTM and TAT complex levels in the ATG group (Figure 2) . sTM elevation in the ATG group rather seemed to persist on days 0 and 3 after HSCT, whereas D-Dimer, TF and TAT complex levels showed a decrease on days 0 and 3 in the ATG group compared to the control group. No differences between the two groups could be detected with regard to global coagulation tests such as PT, aPTT as well as AT III and PAI-1antigen (Table 3 ). Only plasma fibrinogen was slightly increased in the ATG group starting day À1. There was also no increased rate of thromboembolic complications or bleeding manifestations in the ATG-F group compared to the control group. Two patients in each group developed VOD in the further course of their disease. Five of the 12 patients in the ATG group had other side effects such as fever, chills and rash. In two cases, these reactions were severe but could be controlled by steroids and temporarily pausing the ATG infusion. In no case ATG therapy had to be ceased because of these side effects. There was no correlation between patients suffering from these ATG side effects and the development and degree of observed hypercoagulability.
Owing to their underlying hematological disease, several patients in both groups had thrombocytopenia before initiation of ATG treatment. In the ATG group, four patients had marked thrombocytopenia (o30/nl) and in the non-ATG group two patients had mild thrombocytopenia (o100/nl). The platelet count of the remaining patients in each group was analyzed in relation to ATG therapy ( Figure 3 ). We observed a more pronounced and significant decrease in platelet counts in the ATG group as compared to the Non-ATG group.
Discussion
The aim of our study was to assess the effect of ATG-F on the hemostatic system in patients treated with ATG-F as part of their conditioning regimen for HSCT from unrelated donors. The rationale for this study was our observation of constantly increased D-Dimer levels in patients during ATG-F therapy. In one case, ATG treatment was associated with the clinical manifestation of overt DIC (unpublished observation). This finding prompted us to investigate whether ATG causes a systemic activation of the hemostatic system. Non-overt DIC due to ATG treatment in unrelated HSCT M Weber et al
Although our study included only a small number of patients and was conducted in a nonrandomized fashion, our data clearly show a temporary and reversible state of a systemic hypercoagulability related to ATG-F treatment. We found significantly increased levels of D-Dimer, TF and TAT complexes during ATG treatment as compared with the control group. According to the definition of overt and non-overt DIC proposed by the subcommittee of the International Society of Thrombosis and Hemostasis, 25 our finding of a temporary activated, but still compensated, coagulation system because of ATG treatment could be interpreted as nonovert DIC.
No case of overt DIC was observed during the study period and we could not detect any differences between the two groups with regard to global coagulation tests or the incidence of bleeding manifestations, thromboembolic complications or the development of VOD.
Considering the fact that the majority of patients in both groups were treated with identical conditioning regimens (7ATG-F), we conclude that the observed state of hypercoagulability is solely because of ATG-F therapy itself and cannot be explained by the use of different Values indicate mean7s.d. for each parameter in patients treated with ATG ('+ATG', n=12) or without ATG ('ÀATG', n=10). ATG-F was adminstered on days À3, À2 and À1 prior to HSCT. Apart from a rise in plasma fibrinogen (FG) starting on day -1 in the ATG group, all other values in both groups are within normal limits. conditioning regimens or by the administration of methylprednisolone or clemastine prior to ATG treatment. Our data are also in accordance with the findings of Pihusch et al 13 who report a similar temporary state of hypercoagulability as part of a systemic inflammatory syndrome in patients treated with ATG-F prior to HSCT. They found that patients who had received ATG over a period of 4 h and a lower dosage of prednisolone prior to ATG treatment showed a significantly pronounced increase of D-Dimer levels compared to patients treated over a period of 12 h and with higher dosages of pre-emptive steroids.
Previous studies have demonstrated an ATG-triggered release of cytokines inducing TNF-a and IL-6. 11, 13 In conjunction with our observation of increased levels of TF, sTM and TAT complexes in patients treated with ATG, we conclude that the underlying mechanism of nonovert DIC is a cytokine-induced release of tissue factor into the circulation. Potential sources of active tissue factor in this pathological condition could be cytokine-activated peripheral blood monocytes, 26, 27 endothelial cells [28] [29] [30] or platelets. 31 Our finding of increased levels of sTM as a marker of endothelial activity and inury 30 indicates a cytokinetriggered disturbance of the endothelium, which may be an important factor in the induction of nonovert DIC because of ATG treatment. The generation and presence of microparticles resulting from the interaction of monocytes and platelets seems to be another important mediator of procoagulant activity. 32, 33 We also observed a more pronounced decrease in platelet counts in ATG patients as compared to the control group. Platelet aggregation and thrombocytopenia are well known side effects of ATG therapy 8, 9 and are also used as major definition criteria for diagnosing overt and nonovert DIC. 25 Therefore, the more pronounced drop in platelet counts in the study group could be interpreted as part of the ATGinduced nonovert DIC. Platelet aggregation and activation because of ATG 8 may perpetuate the state of hypercoagulability through release of TF.
31,33 PAI-1 was not significantly increased in patients treated with ATG-F. Thus, and in contrast to previous reports, 11 we do not think that impairment of fibrinolytic activity is responsible for the observed state of hypercoagulability. The elevation of plasma fibrinogen starting on day À1 in the ATG group could be explained as part of the acute inflammatory response.
We could not detect any difference in D-Dimer, TF, sTM and TAT complex levels in terms of different ATG dosages. Therefore, we conclude tentatively that ATG-induced hypercoagulability may not be dose-related. In our study, we only used ATG-F of rabbit source and thus a comparison between different ATG preparations was not possible. Consequently, we cannot rule out the possibility that the observed effect is to some extent a specific biological property of the ATG preparation we used in our conditioning regimens. To our knowledge, only the study conducted by Goldmann et al 11 compared the effect of different ALG preparations with regard to their specific potential to induce alterations in the hemostatic system. The authors also observed a state of hypercoagulability indicated by elevated D-Dimer levels regardless which of the different ATG/ALG preparation was used. Interestingly, the effect was less pronounced in patients receiving murine OKT-3 or ATG of horse origin than in patients treated with ATG of rabbit origin.
Apart from different ATG preparations, the time period over which ATG is administered seems to play a crucial role. 13 We therefore recommend administration of ATG as a continuous infusion over 12 h with sufficient pre-emptive steroid medication (2-3 mg/kg) to avoid the development of overt DIC. With regard to the proven efficiency of in vivo T-cell depletion by polyclonal ATG for the prevention of GVHD, [1] [2] [3] [4] this study may provide useful information for the treating physician concerning a potential hazardous side effect of ATG therapy.
